Nvidia and Eli Lilly Forge $1 Billion AI Drug Discovery Partnership
Nvidia (NVDA) and Eli Lilly (LLY) shares climbed after announcing a joint $1 billion investment to establish an AI-driven drug discovery lab in San Francisco. The collaboration leverages Nvidia's computational prowess and Lilly's pharmaceutical datasets to accelerate development timelines—a MOVE Lilly CEO David Ricks claims could "reinvent drug discovery."
The initiative expands on existing ties between the companies, including Lilly's October 2023 announcement of an AI factory powered by Nvidia systems. While both stocks have gained year-to-date, Lilly's 20% monthly surge notably outpaces the broader market.
Nvidia CEO Jensen Huang emphasized AI's transformative potential for life sciences during Monday's announcement. The chipmaker continues diversifying its AI applications, recently revealing autonomous vehicle partnerships with Mercedes-Benz and unveiling open-source Alpamayo models for self-driving training at CES 2026.